Introduction: During postmastectomy radiotherapy (PMRT), it is recommended to boost the postmastectomy surgical scar with additional 10 Gy in 5 fractions in the patients with close or positive surgical margins. The electron beam therapy, though cumbersome, is usually preferred since it has the desired rapid fall of a dose beyond R85. An alternative but easier and reproducible treatment method for PMRT surgical scar boost using 3D CT image-based HDR surface mould brachytherapy is introduced and analyses of the target coverage and dose nearby organs-at-risk (OARs) using this method are evaluated in this study. Methods and Materials: This study includes twelve patients (five left-sided and seven right-sided chest wall), who were planned and treated with CT-image based surface mould HDR brachytherapy for chest wall scar boost (CWB) using Catheter Flap SetTM (Varian Medical Systems, USA) that were given concurrently during external beam radiotherapy (EBRT) treatments. Since no guidelines are available for delineating clinical target volume (CTV) structure to be used for postmastectomy scar boost, the CTV in this study was a uniform 5-mm thick volume drawn at 5 mm beneath the skin (CTVhdr_evl) and its extent was made conforming to the boost area marked on the skin and made visible in CT images by radiopaque wires. Results: Prescribed dose (PD) to CTVhdr_evl is 7.5 Gy in 3 fractions, and 2.5 Gy per fraction. The CTVhdr_evl volume receives the PD with mean V100%, V98% and V95% values which are 98.57%, 99.63% and 100% respectively. The mean dose for heart (MHD) is 2.71 Gy in left-sided CWB and 1.80 Gy in right-sided CWB plans. Mean lung dose (MLD) is 2.48 Gy for ipsilateral lung and 0.76 Gy for contralateral lung. Maximum dose to contralateral breast is 4.93 Gy and the mean dose is 0.79 Gy. The mean percent dose to the skin volume overlying the CTVhdr_evl is 138.6% and 3.7% of skin volume received 200% of the PD. Conclusion: The 3D image-based HDR surface mould achieved good CTV coverage with acceptable doses to OARs. Patient preparation, treatment planning, and execution in this method are less cumbersome and reproducible. Thus surface mould using flap applicator can be used whenever postmastectomy surgical scar boost is required.
Cite this paper
N. Vijayaprabhu, K. Gunaseelan, N. Vivekanandan, N. Karthik, C. Shamsudheen and K. Reddy, "Postmastectomy Scar Boost Irradiation Using HDR Surface Mould Brachytherapy by 3D Image-Based Volume Optimization," International Journal of Medical Physics, Clinical Engineering and Radiation Oncology
, Vol. 2 No. 4, 2013, pp. 139-146. doi: 10.4236/ijmpcero.2013.24019
 R. Arriagada, L. E. Rutqvist and M. G. Le, “Postmastectomy Radiotherapy: Randomized Trials,” Seminars in Radiation Oncology, Vol. 9, No. 3, 1999, pp. 275-286.
 T. A. Buchholz, E. A. Strom, G. H. Perkins and M. D. McNeese, “Controversies Regarding the Use of Radiation after Mastectomy in Breast Cancer,” The Oncologist, Vol. 7, No. 6, 2002, pp. 539-546.http://dx.doi.org/10.1634/theoncologist.7-6-539
 L. B. Marks, J. Zeng and L. R. Prosnitz, “One to Three versus Four or More Positive Nodes and postmastectomy Radiotherapy. Time to End the Debate,” Journal of Clinical Oncology, Vol. 26, No. 13, 2008, pp. 2075-2077.http://dx.doi.org/10.1200/JCO.2007.15.5200
 N. S. Russell, I. H. Kunkler, G. V. Tienhoven, P. A. Canney, J. Thomas, J. Bartlett, et al., “Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?” Journal of Clinical Oncology, Vol. 27, No. 6, 2009, pp. 996-1001.http://dx.doi.org/10.1200/JCO.2008.18.7062
 M. Overgaard, P. S. Hansen, J. Overgaard, C. Rose, M. Andersson and F. Bach, et al., “Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial,” The New England Journal of Medicine, Vol. 337, No. 14, 1997, pp. 949-955.http://dx.doi.org/10.1056/NEJM199710023371401
 M. Overgaard, M. B. Jensen, J. Overgaard, P. S. Hensen, C. Rose, M. Andersson, et al., “Postoperative Radiotherapy in High-Risk Postmenopausal Breast-Cancer Patients Given Adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group 82c Randomized Trial,” Lancet, Vol. 353, No. 9165, 1999, pp. 1641-1648.http://dx.doi.org/10.1016/S0140-6736(98)09201-0
 M. Overgaard, H. M. Neilsoen and J. Overgaard, “Is the Benefit of Postmastectomy Irradiation Limited to Patients with Four or More Positive Nodes, as Recommended in International Consensus Reports? A Subgroup Analysis of the DBCG 82 b&c Randomized Trials,” Radiotherapy & Oncology, Vol. 82, No. 3, 2007, pp. 247-253.http://dx.doi.org/10.1016/j.radonc.2007.02.001
 J. Ragaz, I. A. Olivotto, J. J. Spinelli, N. Phillips, S. M. Jackshon, K. S. Wilson, et al., “Locoregional Radiation Therapy in Patients with High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial,” Journal of the National Cancer Institute, Vol. 97, No. 2, 2005, pp. 116-126.http://dx.doi.org/10.1093/jnci/djh297
 H. M. Nielson, M. Overgaard, C. Grau, A. R. Jenson and J. Overgaard, “Study of Failure Pattern among High-Risk Breast Cancer Patients with or without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies,” Journal of Clinical Oncology, Vol. 24, No. 15, 2006, pp. 2268-2275. http://dx.doi.org/10.1200/JCO.2005.02.8738
 A. Recht, R. Gray, N. E. Davidson, B. L. Fowble, L. J. Solin, F. J. Cummins, et al., “Locoregional Failure 10 Years after Mastectectomy and Adjuvant Chemotherapy with or without Tamoxifen without Irradiation: Experience of the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, Vol. 17, No. 6, 1999, pp. 1689-1700.
 M. E. Taylor, B. G. Haffty, R. Rabinovitch, D. W. Arthur, F. E. Halberg, E. A. Strom, et al., “ACR Appropriateness Criteria? on Postmastectomy Radiotherapy,” International Journal of Radiation Oncology*Biology*Physics, Vol. 73, No. 4, 2009, pp. 997-1002.